BIIB
Biogen·NASDAQ
--
--(--)
--
--(--)
6.23 / 10
Outperform
Sentiment scores 6.23 (Outperform) and fund‑flow reaches 8.08, classified excellent, with strong inflows across most investor sizes except medium. Analyst consensus is bearish: a single HSBC analyst rates Sell (100%). Thus, liquidity is robust but expert outlook remains negative.
Fund Flow Rating
Analyst RatingSell
Wall Street Opinions
Sell
Strong Buy
0%
Buy
0%
Hold
0%
Sell
100%
Strong Sell
0%
Date2026-03-17
InstitutionHSBC
Times predicted2
Historical Win Rate100.0%
Is money flowing into or out of BIIB?
- BIIB holds a Bearish analyst rating, with 100% of experts assigning a Sell grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 6.23/10 (Outperform).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
